Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases

Medicine

Volumn 86, Issue 4, 2007, Pages 242-251

  Ramos Casals, Manuel ^a,c   Brito Zerón, Pilar ^a   Muñoz, Sandra ^a   Soria, Natalia ^a   Galiana, Diana ^a   Bertolaccini, Laura ^b   Cuadrado, Maria Jose ^b   Khamashta, Munther A ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANAPHYLACTOID PURPURA; ANKYLOSING SPONDYLITIS; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CLINICAL FEATURE; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTOCLASTIC VASCULITIS; LUNG HEMORRHAGE; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NECROTIZING ARTERITIS; PERIPHERAL NEUROPATHY; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROGNOSIS; PSORIATIC ARTHRITIS; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TEMPORAL ARTERITIS; URTICARIA; VASCULITIS;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIPHOSPHOLIPID SYNDROME; ARTHRITIS; CROHN DISEASE; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUNG DISEASES, INTERSTITIAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MYOSITIS; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 34447505845     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b013e3181441a68     Document Type: Article

References (89)

1. Ali Y, Shah S. Infliximab-induced systemic lupus erythematosus. Ann Intern Med. 2002;137:625-626.
2. Anandacoomarasamy A, Kannangara S, Barnsley L. Cutaneous vasculitis associated with infliximab in the treatment of rheumatoid arthritis. Intern Med J. 2005;35:638-640.
3. Benucci M, Li Gobbi F, Fossi F, Manfredi M, Del Rosso A. Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. J Clin Rheumatol. 2005;11:47-49.
4. Bieber J, Kavanaugh A. Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheum Dis Clin North Am. 2004;30:257-270.
5. Bleumink GS, ter Borg EJ, Ramselaar CG, Ch Stricker BH. Etanerceptinduced subacute cutaneous lupus erythematosus. Rheumatology (Oxford). 2001;40:1317-1319.
6. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and metaanalysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285.
7. Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med. 1999;131:634.
8. Cairns AP, Duncan MK, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis. 2002;61:1031-1032.
9. Carlson E, Rothfield N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. 2003;48:1165-1166.
10. Chadha T, Hernandez JE. Infliximab-related lupus and associated valvulitis: a case report and review of the literature. Arthritis Rheum. 2006;55:163-166.
11. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43: 2383-2390.
12. Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol. 2004;33:276-277.
13. Christopher-Stine L, Wigley F. Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease. J Rheumatol. 2003;30:2725-2727.
14. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
15. Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy. J Rheumatol. 2006;33:24-30.
16. Courtney PA, Alderdice J, Whitehead EM. Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum. 2003;49:617.
17. Cunnane G, Warnock M, Fye KH, Daikh DI. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum. 2002;47:445-449.
18. De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X; Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7:R545-R551.
19. Doulton TW, Tucker B, Reardon J, Velasco N. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol. 2004;62:234-238.
20. Duffy TN, Genta M, Moll S, Martin PY, Gabay C. Henoch Schonlein purpura following etanercept treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:S106.
21. Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak RB, Paran D, Levartovsky D, Litinsky I, Caspi D. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity. 2005;38:155-160.
22. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005;64:403-407.
23. Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus. 2002;11:753-755.
24. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7:R666-R676.
25. Font J, Cervera R, Ramos-Casals M, Garcia-Carrasco M, Sents J, Herrero C, del Olmo JA, Darnell A, Ingelmo M. Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum. 2004;33:217-230.
26. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol. 2000;27:2041-2044.
27. Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, Tsuji WH, Leff JA. Long-term safety, efficacy and radiographic outcomes with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol. 2005;32:1232-1242.
28. Gonzalez-Gay MA, Garcia-Porrua C, Pujol RM. Clinical approach to cutaneous vasculitis. Curr Opin Rheumatol. 2005;17:56-61.
29. Gonzalez-Lopez MA, Blanco R, Gonzalez-Vela MC, Fernandez-Llaca H, Rodriguez-Valverde V. Development of sarcoidosis during etanercept therapy. Arthritis Rheum. 2006;55:817-820.
30. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum. 2005;34:7-11.
31. Haraoui B, Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol. 2006;18:96-100.
32. Hennum J, Nace J, Shammash E, Gertner E. Infliximab-associated pneumonitis in rheumatoid arthritis. J Rheumatol. 2006;33:1917-1918.
33. High WA, Muldrow ME, Fitzpatrick JE. Cutaneous lupus erythematosus induced by infliximab. J Am Acad Dermatol. 2005;52:E5.
34. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
35. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, Emery P. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol. 2003;30:2287-2291.
36. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187-192.
37. Juan A, Ribas B, Nadal C, Ros I. Treating leukocytoclastic vasculitis associated with etanercept therapy. Is it necessary to stop etanercept? J Rheumatol. 2005;32:2061.
38. Kang MJ, Lee YH, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci. 2006;21:946-949.
39. Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis. 2003;9:176-178.
40. Kramer N, Chuzhin Y, Kaufman LD, Ritter JM, Rosenstein ED. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum. 2002;47:670-671.
41. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology. 2003;42:617-621.
42. Lebwohl M, Gottlieb A, Wallis W, Zitnik R. Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis. J Am Acad Dermatol. 2005;52:195.
43. Lee A, Kasama R, Evangelisto A, Elfenbein B, Falasca G. Henoch-Schonlein purpura after etanercept therapy for psoriasis. J Clin Rheumatol. 2006;12:249-251.
44. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH St Clair EW, Keenan GF, van der Heijde D, Marsters PA, Lipsky PE; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50:1051-1065.
45. Martin Carrasco C, Hortal Reina B, Fernandez Vazquez E. [Pulmonary infiltrates after initiation of treatment with infliximab for adult Still's disease] Arch Bronconeumol. 2005;41:355.
46. Martinez-Taboada VM, Val-Bernal JF, Pesquera LC, Fernandez-Llanio NE, Esteban JM, Blanco R, Alonso-Bartolome P, Gonzalez-Vela C, Rodriguez-Valverde V. Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis. Scand J Rheumatol. 2006;35:322-323.
47. McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford). 2002;41:116-117.
48. McIlwain L, Carter JD, Bin-Sagheer S, Vasey FB, Nord J. Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol. 2003;36:411-413.
49. Merkel PA. Drug-induced vasculitis. Rheum Dis Clin North Am. 2001;27:849-862.
50. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862-2869.
51. Mohan N, Edwards ET, Cupps TR, Slifman N, Lee JH, Siegel JN, Braun MM. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004;31:1955-1958.
52. Mor A, Bingham C 3rd, Barisoni L, Lydon E, Belmont HM. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol. 2005;32:740-743.
53. Musial J, Undas A, Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford). 2003;42:1566-1568.
54. Nancey S, Blanvillain E, Parmentier B, Flourie B, Bayet C, Bienvenu J, Fabien N. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and antidouble-stranded DNA autoantibodies in Crohn's disease. Inflamm Bowel Dis. 2005;11:986-991.
55. Novak S, Cikes N. Infliximab-induced lupus or rheumatoid arthritis (RA) overlapping with systemic lupus erythematosus (SLE) unmasked by infliximab. Clin Exp Rheumatol. 2004;22:268.
56. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs. 2005;65:661-694.
57. Orpin SD, Majmudar VB, Soon C, Azam NA, Salim A. Adalimumab causing vasculitis. Br J Dermatol. 2006;154:998-999.
58. O'Shea FD, Marras TK, Inman RD. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum. 2006;55:978-981.
59. Ostor AJ, Chilvers ER, Somerville MF, Lim AY, Lane SE, Crisp AJ, Scott DG. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol. 2006;33:622-628.
60. Pallotta P, Cianchini G, Ruffelli M, Puddu P. Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis. Rheumatology (Oxford). 2006;45:116-117.
61. Panagi S, Palka W, Korelitz BI, Taskin M, Lessnau KD. Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease. Inflamm Bowel Dis. 2004;10:274-277.
62. Pataka A, Tzouvelekis A, Bouros D. Infliximab-induced non-specific interstitial pneumonia and lupus-like eruption. Eur J Intern Med. 2006;17:520.
63. Perez-Garcia C, Maymo J, Lisbona Perez MP, Almirall Bernabe M, Carbonell Abello J. Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab. Rheumatology (Oxford). 2006;45:114-116.
64. Phillips K, Weinblatt M. Granulomatous lung disease occurring during etanercept treatment. Arthritis Rheum. 2005;53:618-620.
65. Quintos-Macasa AM, Quinet R. Enbrel-induced interstitial lung disease. South Med J. 2006;99:783-784.
66. Ramos-Casals M, Nardi N, Lagrutta M, Brito-Zeron P, Bove A, Delgado G, Cervera R, Ingelmo M, Font J. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore). 2006;85:95-104.
67. Richette P, Dieude P, Damiano J, Liote F, Orcel P, Bardin T. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol. 2004;31:2079-2081.
68. Richez C, Dumoulin C, Schaeverbeke T. Infliximab induced chilblain lupus in a patient with rheumatoid arthritis. J Rheumatol. 2005;32:760-761.
69. Roux CH, Brocq O, Albert C, Breuil V, Euller-Ziegler L. Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis. Joint Bone Spine. 2004;71:444-445.
70. Rubin RL. Drug-induced lupus. Toxicology. 2005;209:135-147.
71. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769.
72. Saint Marcoux B, De Bandt M; CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine. 2006;73:710-713.
73. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford). 2004;43:143-147.
74. Sarzi-Puttini P, Ardizzone S, Manzionna G, Atzeni F, Colombo E, Antivalle M, Carrabba M, Bianchi-Porro G. Infliximab-induced lupus in Crohn's disease: a case report. Dig Liver Dis. 2003;35:814-817.
75. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889-894.
76. Schneider SW, Staender S, Schluter B, Luger TA, Bonsmann G. Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis. Arch Dermatol. 2006;142:115-116.
77. Schoe A, van der Laan-Baalbergen NE, Huizinga TW, Breedveld FC, van Laar JM. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum. 2006;55:157-159.
78. Seton M. Giant cell arteritis in a patient taking etanercept and methotrexate. J Rheumatol. 2004;31:1467.
79. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359:579-580.
80. Srivastava MD, Alexander F, Tuthill RJ. Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol. 2005;61:329-336.
81. Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, Moore B, Wolde D, D'Agati VD. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20:1400-1406.
82. Stratigos AJ, Antoniou C, Stamathioudaki S, Avgerinou G, Tsega A, Katsambas AD. Discoid lupus erythematosus-like eruption induced by infliximab. Clin Exp Dermatol. 2004;29:150-153.
83. Swale VJ, Perrett CM, Denton CP, Black CM, Rustin MH. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol. 2003;28:604-607.
84. Tektonidou MG, Serelis J, Skopouli FN. Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. Clin Rheumatol. 2007;26:258-260.
85. Van Rijthoven AW, Bijlsma JW, Canninga-van Dijk M, Derksen RH, van Roon JA. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. Rheumatology (Oxford). 2006;45:1317-1319.
86. Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol. 2006;33:1189-1193.
87. Weatherhead M, Masson S, Bourke SJ, Gunn MC, Burns GP. Interstitial pneumonitis after infliximab therapy for Crohn's disease. Inflamm Bowel Dis. 2006;12:427-428.
88. Wendling D, Streit G, Lehuede G, Toussirot E, Aubin A, Petitjean A. Cutaneous lymphocytic vasculitis during TNFalpha antagonist therapy for polyarthritis. Joint Bone Spine. 2006;73:215-216.
89. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50:1740-1751.